Hereditary Polyposis Syndromes.

Kidambi TD1, Kohli DR2, Samadder NJ3, Singh A4.

Author information

1: Division of Gastroenterology, City of Hope National Medical Center, Duarte, CA, USA.
2: Division of Gastroenterology, Kansas City Veterans Affair Medical Center, Kansas City, MO, USA.
3: Division of Gastroenterology and Hepatology, Department of Clinical Genomics, Mayo Clinic, Phoenix, AZ, USA.
4: Division of Gastroenterology, University of California San Francisco, 505 Parnassus Ave, Room S357, San Francisco, CA, 941943, USA. Aparajita.Singh@ucsf.edu.

Abstract

PURPOSE OF REVIEW:

Colorectal cancer (CRC) is the third most common cancer in the USA and inherited cancer syndromes are responsible for approximately 3-5% of all CRCs. Genetic testing costs have plummeted in recent years; however, awareness and referral of high-risk patients for testing is still very low. We review the salient clinical features, genetics, and management of well-defined gastrointestinal (GI) hereditary polyposis syndromes including familial adenomatous polyposis, MUTYH-associated polyposis, and the hamartomatous polyposis syndromes.

RECENT FINDINGS:

Comprehensive endoscopic surveillance has the potential to prevent the development of GI cancer and to identify early-stage cancer; newer developments like high-definition endoscopes, chromoendoscopy, and the use of cap-assisted endoscopy have shown promise for enhanced lesion detection rates. Several chemoprevention trials have yielded promising results but safety and efficacy data for long-term use is still awaited. Several new polyposis genes have also been identified in the recent years. Multiple societies have recently published updated surveillance guidelines to aid clinicians in the detection and management of patients with hereditary GI polyposis syndromes. Although these syndromes are rare, it is crucial for the clinicians to recognize these in a timely manner, for the appropriate management plans for both the patient and their at risk family members.